| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/03/2009 | US20090218731 Shaped body and method for production of said body |
| 09/03/2009 | US20090217924 Treatment systems and methods |
| 09/03/2009 | DE19521720B4 Insulinanalogonformulierungen Insulin analog formulations |
| 09/03/2009 | DE102008012435A1 New quinazoline compounds are tyrosin-kinase inhibitors e.g. to treat cancer, hematologic or solid tumors, non-Hodgkin tumors or T-cell lymphoma; and for the modulation of the cell cycle, cell differentiation, apoptosis or angiogenesis |
| 09/03/2009 | DE102004028899B4 Verwendung einer Kombination zur präventiven und/oder therapeutischen Behandlung von bakteriell bedingten Infektionserkrankungen oder der Sepsis Using a combination of preventive and / or therapeutic treatment of bacterial infectious diseases or sepsis |
| 09/03/2009 | CA2753754A1 Methods for treating schizophrenia |
| 09/03/2009 | CA2717100A1 Combination anti-cancer agents |
| 09/03/2009 | CA2717034A1 Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease |
| 09/03/2009 | CA2717011A1 Quinolines as inhibitors of farnesyl pyrophosphate synthase |
| 09/03/2009 | CA2716971A1 Chemical compounds having antiviral activity against dengue virus and other flaviviruses |
| 09/03/2009 | CA2716901A1 Process to minimize polymorphism |
| 09/03/2009 | CA2716898A1 Compound having 6-membered aromatic ring |
| 09/03/2009 | CA2716893A1 Use of s-adenosylmethionine (sam) and superoxide dismutase (sod) for the preparation of medicaments for the treatment of alzheimer's disease |
| 09/03/2009 | CA2716855A1 Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177 |
| 09/03/2009 | CA2716830A1 Forms of rifaximin and uses thereof |
| 09/03/2009 | CA2716807A1 Postsurgical adhesion barriers |
| 09/03/2009 | CA2716798A1 Tetrahydrofuropyridones |
| 09/03/2009 | CA2716788A1 Substituted xanthine derivatives |
| 09/03/2009 | CA2716780A1 Prophylactic or therapeutic agent for diabetes or obesity |
| 09/03/2009 | CA2716773A1 Fused heterocyclic derivative and use thereof |
| 09/03/2009 | CA2716757A1 Kit, composition, product or medicament for treating cognitive impairment |
| 09/03/2009 | CA2716755A1 Protein kinase modulators |
| 09/03/2009 | CA2716747A1 Gamma secretase modulators for the treatment of alzheimer's disease |
| 09/03/2009 | CA2716720A1 Pharmaceutical composition |
| 09/03/2009 | CA2716671A1 Implant and method for the manufacture thereof |
| 09/03/2009 | CA2716658A1 Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety |
| 09/03/2009 | CA2716643A1 Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes |
| 09/03/2009 | CA2716613A1 Substituted 4-aminocyclohexane derivatives for the treatment of pain |
| 09/03/2009 | CA2716599A1 Glucokinase activators |
| 09/03/2009 | CA2716578A1 Methods for treating bowel diseases |
| 09/03/2009 | CA2716572A1 Use of lhrh antagonists at non-castrating doses |
| 09/03/2009 | CA2716554A1 Fibrosis inhibitor |
| 09/03/2009 | CA2716501A1 Crystal forms of 2-{2-[(cyclohexyl)methylene]hydrazino}adenosine |
| 09/03/2009 | CA2716499A1 Bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazolo[1,5-a]pyrimidines, methods for preparation and uses thereof |
| 09/03/2009 | CA2716476A1 16 alpha, 17 alpha-acetal glucocorticosteroidal derivatives and their use |
| 09/03/2009 | CA2716466A1 Prophylactic or therapeutic agent for eye disease accompanied by optic nerve disorder |
| 09/03/2009 | CA2716418A1 Agent for enhancing corneal epithelial barrier function |
| 09/03/2009 | CA2716405A1 Combinations for treating hiv-associated pain |
| 09/03/2009 | CA2716397A1 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the .beta.2 adrenergic receptor |
| 09/03/2009 | CA2716396A1 Novel compositions for treatment of diseases related to activated lymphocytes |
| 09/03/2009 | CA2716365A1 Heterocyclic urea derivatives and methods of use thereof-211 |
| 09/03/2009 | CA2716336A1 Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders |
| 09/03/2009 | CA2716316A1 Methods of modulating the activity of the mc5 receptor and treatment of conditions related to this receptor |
| 09/03/2009 | CA2716256A1 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
| 09/03/2009 | CA2716250A1 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
| 09/03/2009 | CA2716223A1 Pyrrolopyrazine kinase inhibitors |
| 09/03/2009 | CA2716128A1 Inhibitors of 11.beta.-hydroxysteroid dehydrogenase type 1 |
| 09/03/2009 | CA2716109A1 Heteroaryl derivatives as cftr modulators |
| 09/03/2009 | CA2716020A1 Pharmaceutical composition |
| 09/03/2009 | CA2715802A1 Pharmaceutical composition for poorly soluble drugs |
| 09/03/2009 | CA2715728A1 Novel 7-substituted derivatives of 3-carboxy-oxadiazino-quinolone, prep aration thereof and use thereof as anti-bacterials |
| 09/03/2009 | CA2715726A1 Novel crystalline forms |
| 09/03/2009 | CA2715349A1 Inhibitors of cell proliferation and uses thereof |
| 09/03/2009 | CA2714942A1 Stabilized single-liquid pharmaceutical composition containing docetaxel |
| 09/03/2009 | CA2714607A1 Hexahydrocyclopentyl[f]indazole carboxamides and derivatives thereof as selective glucocorticoid receptor modulators |
| 09/03/2009 | CA2714604A1 Therapeutic compounds |
| 09/03/2009 | CA2714573A1 Indazole derivatives |
| 09/03/2009 | CA2714500A1 Heterocyclic compounds as inhibitors of cxcr2 |
| 09/03/2009 | CA2714351A1 Novel compositions containing xanthohumol-cyclodextrin complexes |
| 09/03/2009 | CA2714111A1 Tetrahydro-1h-pyrrolo fused pyridones |
| 09/03/2009 | CA2714058A1 2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease |
| 09/03/2009 | CA2713776A1 New macrolides and their use |
| 09/03/2009 | CA2713718A1 Pyrrolopyrazine kinase inhibitors |
| 09/03/2009 | CA2713710A1 Pyrrolopyrazine kinase inhibitors |
| 09/03/2009 | CA2713581A1 Valsartan solid oral dosage forms and methods of making such formulations |
| 09/03/2009 | CA2713324A1 Pyrrolopyrazine kinase inhibitors |
| 09/03/2009 | CA2712990A1 Protein kinase inhibitors and use thereof |
| 09/03/2009 | CA2712583A1 Tetrahydrothieno pyridines |
| 09/03/2009 | CA2712507A1 Pyrrolopyrazine kinase inhibitors |
| 09/03/2009 | CA2711866A1 Use of a homeoprotein of the bicoid family for preventing or treating retinal ganglionic neurone degeneration |
| 09/03/2009 | CA2711733A1 Pyrrolopyrimidinecarboxamides |
| 09/03/2009 | CA2710996A1 5-[1'-(decahydro-7-hydroxy-1,1,3a,7-tetramethyl-1h-cyclopropa[a]naphtalen-4-yl)-3'-methylbutyl]-2,4,6-trihydroxy-1,3-benzenedicarboxaldehyde used as drugs |
| 09/03/2009 | CA2710962A1 Derivatives of 2-heteroaroyl-imidazol[1,2-a]pyridine, preparation thereef and therapeutic application thereof |
| 09/03/2009 | CA2710947A1 Derivatives of 6-heterocyclic-imidazo[1,2-a]pyrroine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 09/03/2009 | CA2710943A1 Derivatives of n-phenyl-imidazo[1,2-.alpha.]pyridine-2-carboxamides, preon thereof and therapeutic application thereof |
| 09/03/2009 | CA2710860A1 Derivatives of n-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 09/03/2009 | CA2710794A1 Derivatives of n-heterocyclic-6-heterocyclic-imidazo[l,2-.alpha.]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 09/03/2009 | CA2709863A1 Azetidine derivatives, their preparation and their application in therapy |
| 09/03/2009 | CA2620242A1 Topical soothing bruise healing preparation |
| 09/02/2009 | EP2096171A1 MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| 09/02/2009 | EP2096170A1 Modulation of glucagon receptor expression |
| 09/02/2009 | EP2096117A1 Process for producing erythromycin derivative |
| 09/02/2009 | EP2096113A1 9-substituted camptothecin derivatives as antitumor compounds |
| 09/02/2009 | EP2096112A2 Thiazoline acid derivatives |
| 09/02/2009 | EP2096111A1 Pyrazoles and use thereof as drugs |
| 09/02/2009 | EP2096109A1 Carboxylic acid derivative |
| 09/02/2009 | EP2096107A1 Derivatives of squaric acid with anti-proliferative activity |
| 09/02/2009 | EP2096106A1 Novel polyamine derivatives |
| 09/02/2009 | EP2096105A1 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
| 09/02/2009 | EP2096104A1 Organic diamines as mGluR7 modulators |
| 09/02/2009 | EP2095874A2 Zeolite Y alkylation catalysts |
| 09/02/2009 | EP2095828A1 Use of S-adenosylmethionine (SAM) and superoxide dismutase (SOD) for the preparation of medicaments for the treatment of Alzeimer's disease |
| 09/02/2009 | EP2095823A1 GM-CSF for treating demyelination |
| 09/02/2009 | EP2095820A1 Fermented milk for improving and/or treating skin and method for producing the same |
| 09/02/2009 | EP2095819A1 N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors |
| 09/02/2009 | EP2095818A1 Use of LHRH antagonists at non-castrating doses |
| 09/02/2009 | EP2095817A1 Therapeutic compositions and methods |
| 09/02/2009 | EP2095816A1 Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety |
| 09/02/2009 | EP2095815A1 Pharmaceutical formulations containing clopidogrel |
| 09/02/2009 | EP2095813A1 Tablet for buccal, sublingual or gingival administration, comprising an effervescent couple |